These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32289128)

  • 21. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
    Adler LA; Goodman DW; Kollins SH; Weisler RH; Krishnan S; Zhang Y; Biederman J;
    J Clin Psychiatry; 2008 Sep; 69(9):1364-73. PubMed ID: 19012818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantifying the Protective Effects of Stimulants on Functional Outcomes in Attention-Deficit/Hyperactivity Disorder: A Focus on Number Needed to Treat Statistic and Sex Effects.
    Biederman J; DiSalvo M; Fried R; Woodworth KY; Biederman I; Faraone SV
    J Adolesc Health; 2019 Dec; 65(6):784-789. PubMed ID: 31350122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.
    Biederman J; Krishnan S; Zhang Y; McGough JJ; Findling RL
    Clin Ther; 2007 Mar; 29(3):450-63. PubMed ID: 17577466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Banaschewski T; Johnson M; Nagy P; Otero IH; Soutullo CA; Yan B; Zuddas A; Coghill DR
    CNS Drugs; 2018 May; 32(5):455-467. PubMed ID: 29790103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A clinican's guide to adult attention-deficit hyperactivity disorder.
    Modesto-Lowe V; Meyer A; Soovajian V
    Conn Med; 2012 Oct; 76(9):517-23. PubMed ID: 23155670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK.
    Zimovetz EA; Joseph A; Ayyagari R; Mauskopf JA
    Eur J Health Econ; 2018 Jan; 19(1):21-35. PubMed ID: 28093662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical practice. Attention deficit-hyperactivity disorder.
    Rappley MD
    N Engl J Med; 2005 Jan; 352(2):165-73. PubMed ID: 15647579
    [No Abstract]   [Full Text] [Related]  

  • 28. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Change in the therapeutic strategy when faced with an inadequate response to the pharmacological treatment of attention deficit hyperactivity disorder].
    Gandía-Benetó R; Mulas F; Roca P; Ortiz-Sánchez P; Abad-Mas L
    Rev Neurol; 2015 Feb; 60 Suppl 1():S13-8. PubMed ID: 25726817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Attention-Deficit/Hyperactivity Disorder Trajectories From Childhood to Young Adulthood: Evidence From a Birth Cohort Supporting a Late-Onset Syndrome.
    Caye A; Rocha TB; Anselmi L; Murray J; Menezes AM; Barros FC; Gonçalves H; Wehrmeister F; Jensen CM; Steinhausen HC; Swanson JM; Kieling C; Rohde LA
    JAMA Psychiatry; 2016 Jul; 73(7):705-12. PubMed ID: 27192050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical diagnosis and management of attention deficit hyperactivity disorder in preschool children.
    Kaplan A; Adesman A
    Curr Opin Pediatr; 2011 Dec; 23(6):684-92. PubMed ID: 22045309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [ADHD in adulthood: Diagnostics and therapy].
    Groß S; Figge C; Matthies S; Philipsen A
    Nervenarzt; 2015 Sep; 86(9):1171-8; quiz 1179-80. PubMed ID: 26341837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical practice. Attention deficit-hyperactivity disorder in children and adolescents.
    Feldman HM; Reiff MI
    N Engl J Med; 2014 Feb; 370(9):838-46. PubMed ID: 24571756
    [No Abstract]   [Full Text] [Related]  

  • 34. Attention deficit hyperactivity disorder in children: moving forward with divergent perspectives.
    Halasz G; Vance AL
    Med J Aust; 2002 Nov; 177(10):554-7. PubMed ID: 12429005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis and management of ADHD: a new way forward?
    Brimble MJ
    Community Pract; 2009 Oct; 82(10):34-7. PubMed ID: 19899506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of eating disorders with concurrent ADHD symptoms: knowledge, knowledge gaps and clinical implications].
    Svedlund NE; Norring C; Ginsberg Y; von Hausswolff-Juhlin Y
    Lakartidningen; 2019 Sep; 116():. PubMed ID: 31529419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AAP releases guideline on diagnosis, evaluation, and treatment of ADHD.
    Hauk L
    Am Fam Physician; 2013 Jan; 87(1):61-2. PubMed ID: 23317027
    [No Abstract]   [Full Text] [Related]  

  • 38. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
    Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Approach to Evaluating and Managing Adult Attention-Deficit/Hyperactivity Disorder in Primary Care.
    Huang H; Huang H; Spottswood M; Ghaemi N
    Harv Rev Psychiatry; 2020; 28(2):100-106. PubMed ID: 32134834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [An update on the pharmacological treatment of attention deficit hyperactivity disorder: lisdexamphetamine and extended-release guanfacine].
    Martin Fernandez-Mayoralas D; Fernandez-Perrone AL; Munoz-Jareno N; Fernandez-Jaen A
    Rev Neurol; 2017 Mar; 64(s02):S1-S8. PubMed ID: 28272733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.